The COVID-19 pandemic has increased interest in pharmaceutical manufacturing supply chains and ensuring their stability. But any conversations regarding potential changes to these complex supply chains must begin with accurate information. Efforts to ensure a safe, stable and secure supply chain have long been a priority for the biopharmaceutical industry. Over decades, biopharmaceutical manufacturers have carefully built robust global supply chains to ensure patients in the United States and around the world have ongoing access to medicines.